Showing results (311-320 of 378) with videos related to
Sort By:
Pageof 38
Journal of the National Cancer Institute|July 28, 2011
Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortiumDaniele Campa, Rudolf Kaaks, Loïc Le Marchand, et al.European Journal of Human Genetics : EJHG|August 24, 2018
Correction: Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriersLogan C Walker, Louise Marquart, John F Pearson, et al.Breast Cancer Research and Treatment|January 25, 2007
Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriersJoanne Kotsopoulos, Jan Lubinski, Henry T Lynch, et al.Cancer Research|July 30, 2011
Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting GenesTimothy R Rebbeck, Nandita Mitra, Susan M Domchek, et al.Journal of the National Cancer Institute|February 21, 2014
Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling project resultsLouise A Brinton, Michael B Cook, Valerie McCormack, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
The Neoadjuvant Model Is Still the Future for Drug Development in Breast CancerAngela DeMichele, Douglas Yee, Donald A Berry, et al.JAMA Oncology|February 14, 2020
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 TrialRita Nanda, Minetta C Liu, Christina Yau, et al.American Journal of Epidemiology|September 27, 2014
Additive interactions between susceptibility single-nucleotide polymorphisms identified in genome-wide association studies and breast cancer risk factors in the Breast and Prostate Cancer Cohort ConsortiumAmit D Joshi, Sara Lindström, Anika Hüsing, et al.The New England Journal of Medicine|July 14, 2016
Adaptive Randomization of Neratinib in Early Breast CancerJohn W Park, Minetta C Liu, Douglas Yee, et al.Cancer Cell|June 18, 2021
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialLajos Pusztai, Christina Yau, Denise M Wolf, et al.Pageof 38